

11 June 2019

NSX Announcement

STRATEGIC JOINT RESEARCH COLLABORATION BETWEEN BERONI GROUP AND TIANJIN UNIVERSITY

Beroni Group Limited (NSX: BTG, OTCQX: BNIGF) (“Beroni Group” or the “Company”) and the School of Pharmaceutical Science and Technology of Tianjin University have signed a strategic joint research collaboration agreement to jointly share scientific knowledge and develop new technologies.

Tianjin University, established in 1895, is one of the oldest universities in China. Its School of Pharmaceutical Science and Technology has collaborated with many domestic and international commercial entities in developing and implementing new drugs and technologies.

The Head of the School of Pharmaceutical Science and Technology of Tianjin University, Prof. Jay S. Siegel said “It is a privilege to be able to cooperate with Beroni Group. Our School is an internationally focused research institute, and it resonates to collaborate with an internationally focused biotechnology company like Beroni Group. We hope this cooperation will bring good outcome and mutual benefits.”

“We are pleased to be able to partner with Tianjin University’s School of Pharmaceutical Science and Technology to conduct joint research and share technical knowledge and expertise. We will also use our international resources to provide an international platform for Tianjin University to conduct its research programs. We hope to embark on a few joint research initiatives soon.” said Beroni Group’s Chairman, Mr. Jacky Zhang.

The Company will keep the market updated as to the progress of its collaboration with Tianjin University.

For further information please contact:

Mr Jacky Zhang
Executive Chairman
Tel: +86 1851 6931 911
E: 1710426553@qq.com

Mr Peter Wong
Executive Director and CFO
Tel: +61 423 727 580
E: pwong@asiainvest.com.au

About Beroni Group Limited (NSX:BTG) (OTCQX:BNIGF)

Beroni Group is an international biotechnological company listed on the National Stock Exchange of Australia and on the OTC markets in the U.S.A.. It currently has four core businesses - cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases.

Beroni Group’s overall strategic goal is to become a world’s leading enterprise in the biotechnology, life sciences and environmental science industries.